Your browser doesn't support javascript.
loading
Topically applied mometasone furoate improves dysphagia in adult eosinophilic esophagitis - results from a double-blind, randomized, placebo-controlled trial.
Tytor, Jakob; Larsson, Helen; Bove, Mogens; Johansson, Leif; Bergquist, Henrik.
Afiliação
  • Tytor J; Department of Otorhinolaryngology, NU Hospital Group, Trollhättan, Sweden.
  • Larsson H; Department of Otorhinolaryngology, NU Hospital Group, Trollhättan, Sweden.
  • Bove M; Department of Otorhinolaryngology, NU Hospital Group, Trollhättan, Sweden.
  • Johansson L; Department of Otorhinolaryngology, Skaraborg Hospital, Skövde, Sweden.
  • Bergquist H; Department of ENT/H&N Surgery, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden.
Scand J Gastroenterol ; 56(6): 629-634, 2021 06.
Article em En | MEDLINE | ID: mdl-33831327
ABSTRACT

OBJECTIVES:

Topical corticosteroids are considered a cornerstone in the treatment of patients with eosinophilic esophagitis. The aim of this study was to evaluate the benefit of using mometasone furoate spray versus placebo on dysphagia and health-related quality of life in these patients. MATERIAL AND

METHODS:

Consecutive, newly diagnosed adult patients with eosinophilic esophagitis were randomized and treated with either 200 micrograms of orally administered topical mometasone furoate or placebo 4 times daily for 8 weeks. Symptoms and quality of life were evaluated using questionnaires including the Watson Dysphagia Scale, the European Organization for Research and Treatment of Cancer Quality of Life-Oesophageal Module 18 and the Short Form-36 before and after treatment.

RESULTS:

In the intention-to-treat analysis (n = 36) the Watson Dysphagia Scale score after mometasone treatment was reduced by 6.5 (median, p < .01) compared with 0 (median, ns) in the placebo group. The benefit of mometasone over placebo was significant (p < .05). In the per-protocol analysis (n = 33) the Watson Dysphagia Scale score was reduced by 5 (median, p = .01) after mometasone treatment compared with 0 (median, ns) in the placebo group. The advantage of mometasone over the placebo was significant (p < .05). The benefit of using mometasoneas evaluated by the two quality of life questionnaires was, however, insignificant.

CONCLUSIONS:

Our finding suggests that in adult patients with eosinophilic esophagitis, topical mometasone furoate exerts a beneficial effect compared with placebo regarding the main symptom, i.e., dysphagia. A corresponding benefit could not be verified regarding the various quality of life measurements. CLINICAL TRIAL REGISTRATION Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study ClinicalTrials.gov Identifier (NCT02113267).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pregnadienodiois / Transtornos de Deglutição / Esofagite Eosinofílica Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Aspecto: Patient_preference Limite: Adult / Humans Idioma: En Revista: Scand J Gastroenterol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pregnadienodiois / Transtornos de Deglutição / Esofagite Eosinofílica Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Aspecto: Patient_preference Limite: Adult / Humans Idioma: En Revista: Scand J Gastroenterol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia